Finger-prick INR testing offers a convenient point-of-care alternative to traditional venous blood sampling for patients with antiphospholipid syndrome (APS), but its use requires careful consideration. This blog explains how both methods work, outlining the advantages of finger-prick testing—such as speed, accessibility, and potential for home monitoring, alongside the continued role of venous testing as the gold standard due to its accuracy and reliability, particularly in APS where test interference can occur. It also highlights the importance of validation, clinical supervision, and confirmatory venous testing where needed to ensure safe and effective anticoagulation management.
Finger-prick Testing versus Venous Blood testing to measure INR in Antiphospholipid (Hughes’) Syndrome
Many patients with APS (Hughes’ Syndrome) require long-term anticoagulation with vitamin K antagonists such as warfarin. The effectiveness of Warfarin and other Vitamin K dependent anticoagulants is measured by determining the International Normalised Ratio (INR).
Traditionally, INR monitoring has been performed using venous blood sampling analysed in a laboratory usually in an anticoagulation clinic attached to a hospital or GP practice. This approach remains the gold standard, providing accurate and reproducible results. Venous testing is particularly important in APS because lupus anticoagulants and antiphospholipid antibodies can occasionally interfere with blood clotting tests, potentially affecting INR measurements. Laboratory-based testing also allows quality-controlled analysis and facilitates investigation of unexpected results.
Point-of-care (POC) finger-prick testing offers an attractive alternative for many patients. Using a small capillary blood sample obtained from a fingertip, portable devices can provide INR results within seconds. This is often done in an hospital or GP surgery setting but can also sometimes be done at home reducing the need for hospital visits and improving convenience, although should in this circumstance always be done with the approval and guidance of an anticoagulation clinic or GP surgery. This is however, beneficial for patients who require frequent monitoring, have mobility limitations, or live far from blood monitoring centres. Home INR monitoring may also improve patient autonomy and satisfaction.
However, the use of POC finger-prick INR testing in APS requires caution. While some studies have suggested good correlation between methods, other studies have demonstrated that some devices show reduced accuracy in patients with lupus anticoagulants, particularly at higher INR values. Discrepancies between capillary and laboratory INR measurements can lead to inappropriate anticoagulant dose adjustments.
In practice, both approaches have important roles. Venous blood sampling remains the reference standard and may be preferable for patients with unstable anticoagulation, or complex APS. Finger prick testing can provide a convenient and effective monitoring strategy for selected patients when appropriately validated and supervised.
Hughes APS Trust therefore recommends that APS patients undergoing home finger prick monitoring should have parallel venous tests at the start of INR monitoring ensuring validation against laboratory venous samples, and periodically thereafter, and significant changes in INR should ideally be confirmed by venous testing. If done in a hospital or GP setting this POC finger-prick testing validation will normally be done as standard practice.
If you are in any doubt or need advice about your APS care, we recommend you consult your APS specialist.
References
Dr. Arvind Kaul, Hughes APS Trust, June 2026
Share this post: